BL-1020

BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D₂ antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.^[1] In March 2013, it went into the II/III trial phase.^[2] It has been introduced by BioLineRx, a biopharmaceutical development company.

BL-1020

Identifiers
IUPAC name 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
CAS Number	751477-01-7
PubChem CID	11203271
ChemSpider	9378339
UNII	K1WO7H97QZ
ChEMBL	ChEMBL1187646
CompTox Dashboard (EPA)	DTXSID401336321
Chemical and physical data
Formula	C25H33ClN4O2S
Molar mass	489.08 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCOC(=O)CCCN
InChI InChI=1S/C25H33ClN4O2S/c26-20-8-9-24-22(19-20)30(21-5-1-2-6-23(21)33-24)12-4-11-28-13-15-29(16-14-28)17-18-32-25(31)7-3-10-27/h1-2,5-6,8-9,19H,3-4,7,10-18,27H2 Key:BABFYCSPNDKXRI-UHFFFAOYSA-N